Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for ...

Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to ...

Credit: Amgen. The application is supported by data from the phase 2 DeLLphi-301 trial. Results showed 40% of patients responded to treatment with Imdelltra. The Food and Drug Administration (FDA) has ...

Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...

WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial presented at the ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

Overall survival with serplulimab, a novel PD-1 inhibitor being developed in China for extensive-stage small cell lung cancer (ES-SCLC), appears better than that seen with two immune checkpoint ...

Three molecular subtypes of SCLC were identified, with the smoking-related SBS4 signature showing the worst prognosis and lowest tumor mutational burden. The SBS13 signature was associated with a ...

The IMforte trial showed Zepzelca plus Tecentriq improved progression-free and overall survival in extensive-stage SCLC, suggesting a new first-line maintenance standard. DELPHI-304 demonstrated ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant parts ...